Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Central action alpha-1 adrenergic blocker with indications similar to clonidine, used in the treatment of hypertension and attention deficit hyperactivity disorder (ADHD). Oral administration once a day.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic data (low molecular weight, low protein binding and prolonged half-life) make it likely that it would pass into breast milk in amounts which could be significant, although its very high distribution volume would make this difficult.
It can reduce prolactin levels (Hauger 1981), but when lactation is well established, milk production does not depend so much on prolactin levels.
Until more extensive published data about this drug regarding breastfeeding are available a safer alternative drug may be used (Anderson 2018), especially during the neonatal period and/or in case of premature infants.